Brief Telehealth CBT-I Intervention in the Context of the COVID-19 Pandemic

Not Recruiting

Trial ID: NCT04409743

Purpose

The purpose of this study is to investigate whether an empirically validated treatment for insomnia (CBT-I) administered early in the course of sleep disturbance can prevent insomnia disorder or lessen negative mental health outcomes in the wake of the COVID-19 crisis in adults.

Official Title

Harnessing Telehealth to Mitigate the Impact of the COVID-19 Pandemic on Sleep, Suicidality, and Neuropsychiatric Symptoms

Stanford Investigator(s)

Eligibility

Inclusion Criteria:

* Age 18 years or older
* Access to the internet
* Subjective complaint of sleep disturbance (ISI ≥10) that began after March 1, 2020 or the COVID-19 Pandemic (self-reported during DUKE Interview)
* Lives in the United States

Exclusion Criteria:

* Presence of suicidal ideation representing high risk as measured by the Sheehan-Suicide Tracking Scale (S-STS).
* Use of medication specifically prescribed for sleep disturbance and unwilling or unable to discontinue more than one week prior to baseline data collection.
* Current or lifetime history of bipolar disorder or psychosis
* Current substance abuse or dependence
* Not able to verbalize understanding of involvement in research and provide written, informed consent
* Not fluent or literate in English
* Unstable pharmacotherapy for other mental health disorders
* Severe impediment to vision, hearing, and/or hand movement, likely to interfere with the ability to complete assessments, or are unable and/or unlikely to follow study protocols
* Working rotating shift that overlaps with 2400h

Intervention(s):

behavioral: Remote Cognitive Behavioral Therapy for Insomnia

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Andrea Goldstein-Piekarski, PhD
650-497-9414